[Skip to Content]
[Skip to Content Landing]

Durability of Immune Response After COVID-19 Booster Vaccination and Association With COVID-19 Omicron Infection

Educational Objective
To identify the key insights or developments described in this article
1 Credit CME
Key Points

Question  What is the durability of the immune response after 3 vaccine doses, and are antibody kinetics associated with SARS-CoV-2 Omicron infection?

Findings  In this cohort study of 3972 health care workers, reduction in antibody levels 5 months after the third BNT162b2 vaccine dose was slower than after the second, while Omicron's neutralizing response was lower compared with other variants of concern. Peak antibody levels after the third dose were associated with Omicron infection.

Meaning  This study found that the humoral response after the third vaccine dose was sustained for 5 months and that antibody kinetics were associated with Omicron infection.

Abstract

Importance  The BNT162b2 two-dose vaccine (BioNTech/Pfizer) has high effectiveness that wanes within several months. The third dose is effective in mounting a significant immune response, but its durability is unknown.

Objective  To compare antibody waning after second and third doses and estimate the association of antibody kinetics with susceptibility to infection with the Omicron variant of SARS-CoV-2.

Design, Setting, and Participants  In a prospective longitudinal cohort study in a tertiary medical center in Israel, health care workers who received the BNT162b2 vaccine were followed up monthly for IgG and neutralizing antibody levels. Linear mixed models were used to compare antibody titer waning of second and third doses and to assess whether antibody dynamics were associated with Omicron transmission. Avidity, T cell activation, and microneutralization of sera against different variants of concern were assessed for a subgroup.

Exposure  Vaccination with a booster dose of the BNT162b2 vaccine.

Main Outcomes and Measures  The primary outcome was the rate of antibody titer change over time, and the secondary outcome was SARS-CoV-2 Omicron variant infection, as confirmed by reverse transcriptase–polymerase chain reaction.

Results  Overall, 4868 health care workers (mean [SD] age, 46.9 [13.7] years; 3558 [73.1%] women) and 3972 health care workers (mean [SD] age, 48.5 [14.1] years; 996 [74.9%] women) were followed up for 5 months after their second and third vaccine doses, respectively. Waning of IgG levels was slower after the third compared with the second dose (1.32%/d [95% CI, 1,29%/d to 1.36%/d] vs 2.26% [95% CI, 2.13%/d 2.38%/d]), as was waning of neutralizing antibody levels (1.32%/d [95% CI, 1.21%/d to 1.43%/d] vs 3.34%/d [95% CI, 3.11%/d to 3.58%/d]). Among 2865 health care workers assessed for Omicron incidence during an additional 2 months of follow-up, lower IgG peak (ratio of means 0.86 [95% CI, 0.80-0.91]) was associated with Omicron infection, and among participants aged 65 years and older, faster waning of IgG and neutralizing antibodies (ratio of mean rates, 1.40; [95% CI, 1.13-1.68] and 3.58 [95% CI, 1.92-6.67], respectively) were associated with Omicron infection. No waning in IgG avidity was observed 112 days after the third dose. Live neutralization of Omicron was lower compared with previous strains, with a geometric mean titer at the peak of 111 (95% CI, 75-166), compared with 942 (95% CI, 585-1518) for WT, 410 (95% CI, 266-634) for Delta; it demonstrated similar waning to 26 (95% CI, 16-42) within 4 months. Among 77 participants tested for T cell activity, mean (SD) T cell activity decreased from 98 (5.4) T cells/106 peripheral blood mononuclear cells to 59 (9.3) T cells/106 peripheral blood mononuclear cells.

Conclusions and Relevance  This study found that the third vaccine dose was associated with greater durability than the second dose; however, Omicron was associated with greater resistance to neutralization than wild type and Delta variants of concern. Humoral response dynamics were associated with susceptibility to Omicron infection.

Sign in to take quiz and track your certificates

Buy This Activity

JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 Credit(s)™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC

CME Disclosure Statement: Unless noted, all individuals in control of content reported no relevant financial relationships. If applicable, all relevant financial relationships have been mitigated.

Article Information

Accepted for Publication: July 31, 2022.

Published: September 15, 2022. doi:10.1001/jamanetworkopen.2022.31778

Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2022 Gilboa M et al. JAMA Network Open.

Corresponding Author: Mayan Gilboa, MD, Infection Prevention and Control Unit, Sheba Medical Center, Derech Sheba 1, Tel Hashomer, Ramat Gan, Israel (mayangilboa@yahoo.com).

Author Contributions: Drs Gilboa and Regev-Yochay had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Drs Gilboa and Regev-Yochay contributed equally as co–first authors.

Concept and design: Gilboa, Regev-Yochay, Amit, Afek, Kreiss, Lustig.

Acquisition, analysis, or interpretation of data: Gilboa, Regev-Yochay, Mandelboim, Indenbaum, Asraf, Fluss, Amit, Mendelson, Doolman, Freedman, Lustig.

Drafting of the manuscript: Gilboa, Regev-Yochay, Asraf, Fluss, Doolman, Freedman, Lustig.

Critical revision of the manuscript for important intellectual content: Gilboa, Regev-Yochay, Mandelboim, Indenbaum, Amit, Mendelson, Afek, Freedman, Kreiss, Lustig.

Statistical analysis: Asraf, Fluss, Doolman, Freedman.

Obtained funding: Kreiss, Lustig.

Administrative, technical, or material support: Gilboa, Mandelboim, Asraf, Mendelson, Doolman, Afek, Kreiss.

Supervision: Regev-Yochay, Asraf, Mendelson, Doolman, Afek, Kreiss, Lustig.

Conflict of Interest Disclosures: Dr Regev-Yochay reported receiving grants from Pfizer and personal fees from Moderna, AstraZeneca, Teva Pharmaceuticals, and Pfizer outside the submitted work. Dr Lustig reported receiving a grant from Pfizer outside the submitted work. No other disclosures were reported.

Additional Contributions: We would like to thank Sheba Medical Center management, specifically Amir Grinberg, PhD, and Anat Peles Bortz, PhD, for enabling this study. We thank Vered Roa; Esther Rosner, PhD; and Yael Beker-Ilani for coordinating this study and the Sheba information technology team, specifically Osnat Persky, Itay Menaged, and Shay Yamin, for assisting in retrieving data. All individuals mentioned in the acknowledgment section have given written permission to include their names in this segment. None of these individuals were compensated beyond their normal salaries for this work.

References
1.
Del Rio  C , Omer  SB , Malani  PN .  Winter of Omicron—the evolving COVID-19 pandemic.   JAMA. 2022;327(4):319-320. doi:10.1001/jama.2021.24315PubMedGoogle ScholarCrossref
2.
Polack  FP , Thomas  SJ , Kitchin  N ,  et al; C4591001 Clinical Trial Group.  Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine.   N Engl J Med. 2020;383(27):2603-2615. doi:10.1056/NEJMoa2034577PubMedGoogle ScholarCrossref
3.
El Sahly  HM , Baden  LR , Essink  B ,  et al; COVE Study Group.  Efficacy of the mRNA-1273 SARS-CoV-2 vaccine at completion of blinded phase.   N Engl J Med. 2021;385(19):1774-1785. doi:10.1056/NEJMoa2113017PubMedGoogle ScholarCrossref
4.
Bar-On  YM , Goldberg  Y , Mandel  M ,  et al.  Protection of BNT162b2 vaccine booster against COVID-19 in Israel.   N Engl J Med. 2021;385(15):1393-1400. doi:10.1056/NEJMoa2114255PubMedGoogle ScholarCrossref
5.
Amit  S , Regev-Yochay  G , Afek  A , Kreiss  Y , Leshem  E .  Early rate reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients.   Lancet. 2021;397(10277):875-877. doi:10.1016/S0140-6736(21)00448-7PubMedGoogle ScholarCrossref
6.
World Health Organization.  Interim recommendations for use of the Pfizer-BioNTech COVID-19 vaccine, BNT162b2, under emergency use listing. Accessed January 17, 2022. https://www.who.int/publications/i/item/WHO-2019-nCoV-vaccines-SAGE_recommendation-BNT162b2-2021.1
7.
Goldberg  Y , Mandel  M , Bar-On  YM ,  et al.  Waning Immunity after the BNT162b2 vaccine in Israel.   N Engl J Med. 2021;385(24):e85. doi:10.1056/NEJMoa2114228PubMedGoogle ScholarCrossref
8.
Chemaitelly  H , Tang  P , Hasan  MR ,  et al.  Waning of BNT162b2 vaccine protection against SARS-CoV-2 infection in Qatar.   N Engl J Med. 2021;385(24):e83. doi:10.1056/NEJMoa2114114PubMedGoogle ScholarCrossref
9.
Levin  EG , Lustig  Y , Cohen  C ,  et al.  Waning immune humoral response to BNT162b2 Covid-19 vaccine over 6 months.   N Engl J Med. 2021;385(24):e84. doi:10.1056/NEJMoa2114583PubMedGoogle ScholarCrossref
10.
Notarte  KI , Ver  AT , Velasco  JV ,  et al.  Effects of age, sex, serostatus, and underlying comorbidities on humoral response post-SARS-CoV-2 Pfizer-BioNTech mRNA vaccination: a systematic review.   Crit Rev Clin Lab Sci. 2022:1-18. doi:10.1080/10408363.2022.2038539PubMedGoogle ScholarCrossref
11.
Israel Ministry of Health. Vaccines: COVID-19 vaccine. Accessed January 17, 2022. https://corona.health.gov.il/en/vaccine-for-covid/over-12/
12.
Centers for Disease Control and Prevention. Grading of recommendations, assessment, development, and evaluation (GRADE): Pfizer-BioNTech, Moderna, and Janssen COVID-19 booster doses. Accessed January 17, 2022. https://www.cdc.gov/vaccines/acip/recs/grade/covid-19-booster-doses.html
13.
Food and Drug Administration. FDA authorizes booster dose of Pfizer-BioNTech COVID-19 vaccine for certain populations. Accessed January 17, 2022. https://www.fda.gov/news-events/press-announcements/fda-authorizes-booster-dose-pfizer-biontech-covid-19-vaccine-certain-populations
14.
Gilboa  M , Mandelboim  M , Indenbaum  V ,  et al.  Early immunogenicity and safety of the third dose of BNT162b2 messenger RNA coronavirus disease 2019 vaccine among adults older than 60 years: real-world experience.   J Infect Dis. 2022;225(5):785-792. doi:10.1093/infdis/jiab584PubMedGoogle ScholarCrossref
15.
Lustig  Y , Gonen  T , Meltzer  L ,  et al.  Superior immunogenicity and effectiveness of the third compared to the second BNT162b2 vaccine dose.   Nat Immunol. 2022;23(6):940-946. doi:10.1038/s41590-022-01212-3PubMedGoogle ScholarCrossref
16.
Tenforde  MW , Patel  MM , Gaglani  M ,  et al; IVY Network.  Effectiveness of a third dose of Pfizer-BioNTech and Moderna vaccines in preventing COVID-19 hospitalization among immunocompetent and immunocompromised adults—United States, August-December 2021.   MMWR Morb Mortal Wkly Rep. 2022;71(4):118-124. doi:10.15585/mmwr.mm7104a2PubMedGoogle ScholarCrossref
17.
Muik  A , Lui  BG , Wallisch  AK ,  et al.  Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine-elicited human sera.   Science. 2022;375(6581):678-680. doi:10.1126/science.abn7591PubMedGoogle ScholarCrossref
18.
Nemet  I , Kliker  L , Lustig  Y ,  et al.  Third BNT162b2 vaccination neutralization of SARS-CoV-2 Omicron infection.   N Engl J Med. 2022;386(5):492-494. doi:10.1056/NEJMc2119358PubMedGoogle ScholarCrossref
19.
Bergwerk  M , Gonen  T , Lustig  Y ,  et al.  COVID-19 breakthrough infections in vaccinated health care workers.   N Engl J Med. 2021;385(16):1474-1484. doi:10.1056/NEJMoa2109072PubMedGoogle ScholarCrossref
20.
Lustig  Y , Sapir  E , Regev-Yochay  G ,  et al.  BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers.   Lancet Respir Med. 2021;9(9):999-1009. doi:10.1016/S2213-2600(21)00220-4PubMedGoogle ScholarCrossref
21.
Lustig  Y , Zuckerman  N , Nemet  I ,  et al.  Neutralising capacity against Delta (B.1.617.2) and other variants of concern following Comirnaty (BNT162b2, BioNTech/Pfizer) vaccination in health care workers, Israel.   Euro Surveill. 2021;26(26). doi:10.2807/1560-7917.ES.2021.26.26.2100557PubMedGoogle ScholarCrossref
22.
Lustig  Y , Nemet  I , Kliker  L ,  et al.  Neutralizing response against variants after SARS-CoV-2 infection and one dose of BNT162b2.   N Engl J Med. 2021;384(25):2453-2454. doi:10.1056/NEJMc2104036PubMedGoogle ScholarCrossref
23.
Notarte  KI , Guerrero-Arguero  I , Velasco  JV ,  et al.  Characterization of the significant decline in humoral immune response six months post-SARS-CoV-2 mRNA vaccination: a systematic review.   J Med Virol. 2022;94(7):2939-2961. doi:10.1002/jmv.27688PubMedGoogle ScholarCrossref
24.
Bergwerk  M , Gonen  T , Lustig  Y ,  et al.  COVID-19 breakthrough infections in vaccinated health care workers.   N Engl J Med. 2021;385(16):1474-1484. doi:10.1056/NEJMoa2109072PubMedGoogle ScholarCrossref
25.
Feng  S , Phillips  DJ , White  T ,  et al; Oxford COVID Vaccine Trial Group.  Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection.   Nat Med. 2021;27(11):2032-2040. doi:10.1038/s41591-021-01540-1PubMedGoogle ScholarCrossref
26.
Yu  J , Collier  AY , Rowe  M ,  et al.  Neutralization of the SARS-CoV-2 Omicron BA.1 and BA.2 variants.   N Engl J Med. 2022;386(16):1579-1580. doi:10.1056/NEJMc2201849PubMedGoogle ScholarCrossref
27.
Andrews  N , Stowe  J , Kirsebom  F ,  et al.  Covid-19 vaccine effectiveness against the Omicron (B.1.1.529) variant.   N Engl J Med. 2022;386(16):1532-1546. doi:10.1056/NEJMoa2119451PubMedGoogle ScholarCrossref
28.
Ferdinands  JM , Rao  S , Dixon  BE ,  et al.  Waning 2-Dose and 3-dose effectiveness of mRNA vaccines against COVID-19-associated emergency department and urgent care encounters and hospitalizations among adults during periods of Delta and Omicron variant predominance—VISION Network, 10 states, August 2021-January 2022.   MMWR Morb Mortal Wkly Rep. 2022;71(7):255-263. doi:10.15585/mmwr.mm7107e2PubMedGoogle ScholarCrossref
29.
Israel Ministry of Health. Corona dashboard. Accessed August 10, 2021. https://datadashboard.health.gov.il/COVID-19/general
30.
Regev-Yochay  G , Gonen  T , Gilboa  M ,  et al.  Efficacy of a fourth dose of COVID-19 mRNA vaccine against Omicron.   N Engl J Med. 2022;386(14):1377-1380. doi:10.1056/NEJMc2202542PubMedGoogle ScholarCrossref
31.
Magen  O , Waxman  JG , Makov-Assif  M ,  et al.  Fourth dose of BNT162b2 mRNA COVID-19 vaccine in a nationwide setting.   N Engl J Med. 2022;386(17):1603-1614. doi:10.1056/NEJMoa2201688PubMedGoogle ScholarCrossref
32.
Chalkias  S , Harper  C , Vrbicky  K ,  et al. A bivalent Omicron-containing booster vaccine against COVID-19.  medRxiv. Preprint posted online June 25, 2022. doi:10.1101/2022.06.24.22276703
33.
Branche  AR , Rouphael  NG , Diemert  DJ ,  et al; COVAIL Study Group. SARS-CoV-2 variant vaccine boosters trial: preliminary analyses.  medRxiv. Preprint posted online July 15, 2022. doi:10.1101/2022.07.12.22277336
Close
Want full access to the AMA Ed Hub?
After you sign up for AMA Membership, make sure you sign in or create a Physician account with the AMA in order to access all learning activities on the AMA Ed Hub
Buy this activity
Close
Want full access to the AMA Ed Hub?
After you sign up for AMA Membership, make sure you sign in or create a Physician account with the AMA in order to access all learning activities on the AMA Ed Hub
Buy this activity
Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Close

Name Your Search

Save Search
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Close
Close

Lookup An Activity

or

My Saved Searches

You currently have no searches saved.

Close

My Saved Courses

You currently have no courses saved.

Close